Gilead Sciences Inc

NASDAQ: GILD
$97.20
+$5.51 (+6.0%)
Real Time Data Delayed 15 Min.

GILD Articles

The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big...
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Thursday include Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp and Zynga.
24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Alphabet, Amazon.com, General Electric, Gilead Sciences, Intel, Seagate Technology and U.S. Steel.
Monday was a down day for the U.S. markets. Although the markets have been pushing new highs recently, today was not one of those days. Crude oil started the week out on a negative note, pulling back...
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
The top analyst upgrades, downgrades and other research calls from Friday include Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead Sciences, Intel, Starbucks and Yamana Gold.